- Home » News and EventsPage 18

NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Updates for media on the latest products, offerings and developments across our business.
Press Releases
̽»¨ºÏ¼¯ Biologics Invests $50 Million to Add Third High-Speed Vial Line at its Bloomington, Indiana, Facility
Sep 2, 2020
̽»¨ºÏ¼¯ today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.
Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by ̽»¨ºÏ¼¯ Biologics at PEGS
Aug 25, 2020
̽»¨ºÏ¼¯ today announced that two ̽»¨ºÏ¼¯ Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.
̽»¨ºÏ¼¯ Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
Aug 24, 2020
̽»¨ºÏ¼¯ Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at ̽»¨ºÏ¼¯â€™s Harmans, Maryland gene therapy manufacturing facility.
̽»¨ºÏ¼¯ to Discuss a Scalable Gene Therapy Manufacturing Process and Early Development Considerations for Orphan Drugs at Upcoming Industry Congress
Aug 18, 2020
̽»¨ºÏ¼¯ today announced it will present at the upcoming World Orphan Drug Congress Annual Meeting, which will take place virtually on Aug. 24 – 26, 2020.
Post-Brexit European Clinical Supply Solutions to be Discussed by ̽»¨ºÏ¼¯ at Upcoming Forum
Aug 11, 2020
̽»¨ºÏ¼¯ today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’.
̽»¨ºÏ¼¯ Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis’ Gene Therapy
Aug 6, 2020
̽»¨ºÏ¼¯ today announced that it was approved by the U.S. FDA to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy.
̽»¨ºÏ¼¯ Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site
Aug 4, 2020
̽»¨ºÏ¼¯ today announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion will be segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.
̽»¨ºÏ¼¯ Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Jul 29, 2020
̽»¨ºÏ¼¯ will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.
̽»¨ºÏ¼¯ Biologics’ Executive to Discuss Manufacturing Scale-up During a Pandemic
Jul 22, 2020
̽»¨ºÏ¼¯ today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.